Germany's Dresden Becomes Nuclear Medicine Innovation Hub

A quiet revolution in cancer treatment is happening in Dresden, Germany, where scientists are using precisely targeted radiation to destroy tumors while leaving healthy tissue untouched.

The breakthrough centers on theranostics, a combination of diagnostics and therapy that uses low-level radioactive isotopes to both find and treat cancer. Unlike traditional chemotherapy that affects the entire body, these new treatments deliver radiation directly to cancer cells like a guided missile.

Dresden's success stems from decades of groundwork. The city inherited radiopharmaceutical expertise from the former East German Nuclear Research Center, now the Helmholtz Center Dresden-Rossendorf. That foundation has blossomed into a thriving cluster of companies, research centers, and medical facilities working together.

The momentum is attracting serious money. In January, Dresden-based ROTOP Pharmaka secured major investment from SHS Capital and Genui to expand production facilities. The company has spent 25 years perfecting the manufacture of diagnostic and therapeutic radiopharmaceuticals.

"The radiopharmaceutical sector, particularly in radioligand therapy, is on the verge of significant market growth," says Jens Junker, CEO of ROTOP. Market studies predict rapid sales acceleration in coming years for both drug developers and manufacturers.

The official nukliD Radiopharmacy Cluster launched in January 2025, formalizing partnerships between researchers, manufacturers, hospitals, and investors. Dr. Peggy Jungke, the cluster manager, says Dresden already accounts for large parts of the radiopharmaceutical value chain in Central Germany.

The Ripple Effect

Dresden's model shows how regional collaboration drives innovation. The cluster brings together cutting-edge research from the Helmholtz Center, manufacturing expertise from companies like ROTOP, and clinical experience from local hospitals.

Professor Klaus Kopka, who leads radiopharmaceutical tumor research at Helmholtz, credits this teamwork for Dresden's rapid progress. "With our infrastructure and innovative strength, combined with our close ties to clinical centers and industry, we are making this transition a reality," he explains.

The applications extend beyond cancer. New radioisotopes and linking technologies are enabling diagnosis and treatment of neurological diseases like Alzheimer's. The market has grown explosively over the past five years as more conditions become treatable.

Thomas Horn of Saxony Trade & Invest helped identify radiopharmacy as a strategic opportunity early. His organization connected stakeholders, hosted investor events, and helped raise the cluster's profile internationally.

Now Dresden is reaching beyond Germany's borders. The cluster is actively courting international pharmaceutical companies, startups, and additional investors while sharing knowledge across the DACH region (Germany, Austria, Switzerland).

The goal is both ambitious and achievable: make promising treatments available to patients faster while establishing Dresden as the go-to destination for radiopharmaceutical innovation worldwide.